These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24227007)

  • 1. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry.
    Peña L; Gama A; Goldschmidt MH; Abadie J; Benazzi C; Castagnaro M; Díez L; Gärtner F; Hellmén E; Kiupel M; Millán Y; Miller MA; Nguyen F; Poli A; Sarli G; Zappulli V; de las Mulas JM
    Vet Pathol; 2014 Jan; 51(1):127-45. PubMed ID: 24227007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oestrogen and progesterone receptor expression in subtypes of canine mammary tumours in intact and ovariectomised dogs.
    Mainenti M; Rasotto R; Carnier P; Zappulli V
    Vet J; 2014 Oct; 202(1):62-8. PubMed ID: 24980810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
    Gama A; Alves A; Schmitt F
    Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breed-related differences in altered BRCA1 expression, phenotype and subtype in malignant canine mammary tumors.
    Im KS; Kim IH; Kim NH; Lim HY; Kim JH; Sur JH
    Vet J; 2013 Mar; 195(3):366-72. PubMed ID: 22901454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
    Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers.
    Kim NH; Lim HY; Im KS; Kim JH; Sur JH
    J Comp Pathol; 2013 May; 148(4):298-306. PubMed ID: 23079102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
    Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
    J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
    Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
    Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
    van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
    Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
    Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
    Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
    Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
    J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours.
    Maniscalco L; Iussich S; de Las Mulas JM; Millán Y; Biolatti B; Sasaki N; Nakagawa T; De Maria R
    Vet J; 2012 Jan; 191(1):65-71. PubMed ID: 21282070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours.
    Pastor N; Ezquerra LJ; Santella M; Caballé NC; Tarazona R; Durán ME
    Vet Comp Oncol; 2020 Dec; 18(4):753-762. PubMed ID: 32336005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.